19 results on '"Nicolini, Gabriele"'
Search Results
2. Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial.
- Author
-
Papi, Alberto, Nicolini, Gabriele, Crimi, Nunzio, Fabbri, Leonardo, Olivieri, Dario, Rossi, Andrea, and Paggiaro, Pierluigi
- Subjects
- *
ASTHMA treatment , *RANDOMIZED controlled trials , *ASTHMATICS , *ADRENOCORTICAL hormones , *BECLOMETHASONE dipropionate , *FORMOTEROL , *FLUTICASONE , *SALMETEROL - Abstract
Background: Asthma guidelines suggest that therapy can be reduced once asthma is controlled. Despite these recommendations, asthmatic patients are seldom stepped down in clinical practice, and questions remain about when and how to reduce asthma therapy. The purpose of the present study was to evaluate lung function and asthma control in patients who were stepped down from the highest recommended dose of inhaled corticosteroid/long acting β2 agonist combination therapy. Methods: This was a prospective, randomised, controlled, two-arm parallel group study. Asthmatic patients who were fully controlled with a high daily dose (1000/100 μg) of fluticasone/salmeterol were randomly assigned to 6 months of open-label treatment with either 500/100 μg fluticasone/salmeterol Diskus daily or 400/24 μg extrafine beclomethasone/formoterol pMDI daily. The primary outcome was the change in morning peak expiratory flow (PEF) values between baseline and the end of treatment. The secondary outcomes included asthma control and exacerbation frequency. Results: Four hundred twenty-two patients were included in the analysis. The PEF values remained above 95% of the predicted values throughout the study. The end-study morning PEF rates showed equivalence between the groups (difference between means, 2.49 L/min; 95% CI, -13.43 to 18.42). No changes from baseline were detected in PEF and forced expiratory volume in 1 second measured at the clinics, in the symptom scores or in the use of rescue medication. Asthma control was maintained in 95.2% of the patients at 6 months. No significant differences between the groups were detected in any other parameter, including exacerbation frequency and adverse events. Conclusions: Stepping down patients whose asthma is controlled with the highest recommended dose of fluticasone/salmeterol to either 500/100 μg fluticasone/salmeterol daily or 400/24 μg extra-fine beclomethasone/ formoterol daily provides comparable maintenance of lung function and asthma control. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. Inhaled corticosteroid therapy with nebulized beclometasone dipropionate
- Author
-
Nicolini, Gabriele, Cremonesi, Giovanni, and Melani, Andrea S.
- Subjects
- *
CORTICOSTEROIDS , *ANTI-inflammatory agents , *ASTHMA in children , *ANTIASTHMATIC agents , *INHALERS , *BECLOMETHASONE dipropionate , *SYSTEMATIC reviews , *AEROSOL therapy - Abstract
Abstract: Inhaled corticosteroids (ICS) are the most effective anti-inflammatory agents for the management of chronic persistent asthma and are therefore recommended as first-line antiasthmatic therapy in children and adults. In various settings, the administration of ICS via nebulizer rather than hand-held inhaler (HHI) may have certain advantages, as many patients with HHI fail to use these devices properly or efficiently. In particular, young children, the elderly, the acutely ill, and those with restricted dexterity may be unable to coordinate inhalation with actuation of the device or to generate sufficient inspiratory flow to operate breath-actuated devices effectively. Compliance with nebulized therapy may also be better than that with a pressurized metered-dose inhaler (pMDI) plus spacer. Systematic reviews conclude that there is no significant difference in clinical effects between nebulizers and HHI. Performance and clinical effect of nebulization are influenced by several technical aspects such as the nebulizer–drug combination, nebulizer type, output and lung deposition. Among the currently available ICS, nebulized beclometasone dipropionate (BDP) has been in clinical use for more than 35 years, and has demonstrated marked clinical efficacy and a favorable tolerability profile in children and adults with chronic persistent asthma. The clinical efficacy of nebulized beclometasone is discussed in the present review using data from 13 published studies, which included a total of 1250 patients. Three multicenter, randomized, double-blind studies showed that nebulized BDP is as effective as BDP via pMDI plus spacer in a 2:1 dose ratio. Controlled trials involving 497 adults and children demonstrated similar clinical efficacy between nebulized BDP and either nebulized fluticasone propionate or nebulized budesonide. In all these trials, treatment-related adverse effects were generally uncommon, most were mild-to-moderate in severity, and most were associated with the respiratory system. Meta-analyses show that BDP, like other inhaled corticosteroids, has no major influence on patient height, urinary cortisol concentration, or bone metabolism, thus suggesting the absence of growth retardation or any marked effect on adrenal function or the hypothalamic-pituitary-adrenal axis when used in the approved dose range. Overall, nebulized BDP appears to have a particularly important place in asthma therapy: as a general alternative to HHIs (e.g. in patients with poor HHI compliance); when patients such as children or the elderly are unable to operate HHIs because of poor hand–lung coordination, lack of cooperation, or low inspiratory flow rate; and when high dosages of ICS are required, such as in adults with severe, corticosteroid-dependent asthma. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
4. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
- Author
-
Lombardo, Flavia L., Spila Alegiani, Stefania, Mayer, Flavia, Cipriani, Marta, Lo Giudice, Maria, Ludolph, Albert Christian, McDermott, Christopher J., Corcia, Philippe, Van Damme, Philip, Van den Berg, Leonard H., Hardiman, Orla, Nicolini, Gabriele, Vanacore, Nicola, Dickie, Brian, Albanese, Alberto, Puopolo, Maria, Tornese, Paolo, Cocco, Antoniangela, Matteoli, Michela, and Lauranzano, Eliana
- Subjects
- *
CLINICAL trials , *STATISTICS , *COVID-19 , *PATIENT selection , *AMYOTROPHIC lateral sclerosis , *NEURODEGENERATION , *SAFETY - Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a highly debilitating neurodegenerative condition. Despite recent advancements in understanding the molecular mechanisms underlying ALS, there have been no significant improvements in therapeutic options for ALS patients in recent years. Currently, there is no cure for ALS, and the only approved treatment in Europe is riluzole, which has been shown to slow the disease progression and prolong survival by approximately 3 months. Recently, tauroursodeoxycholic acid (TUDCA) has emerged as a promising and effective treatment for neurodegenerative diseases due to its neuroprotective activities. Methods: The ongoing TUDCA-ALS study is a double-blinded, parallel arms, placebo-controlled, randomized multicenter phase III trial with the aim to assess the efficacy and safety of TUDCA as add-on therapy to riluzole in patients with ALS. The primary outcome measure is the treatment response defined as a minimum of 20% improvement in the ALS Functional Rating Scale-Revised (ALSFRS-R) slope during the randomized treatment period (18 months) compared to the lead-in period (3 months). Randomization will be stratified by country. Primary analysis will be conducted based on the intention-to-treat principle through an unadjusted logistic regression model. Patient recruitment commenced on February 22, 2019, and was closed on December 23, 2021. The database will be locked in September 2023. Discussion: This paper provides a comprehensive description of the statistical analysis plan in order to ensure the reproducibility of the analysis and avoid selective reporting of outcomes and data-driven analysis. Sensitivity analyses have been included in the protocol to assess the impact of intercurrent events related to the coronavirus disease 2019. By focusing on clinically meaningful and robust outcomes, this trial aims to determine whether TUDCA can be effective in slowing the disease progression in patients with ALS. Trial registration: ClinicalTrials.gov NCT03800524. Registered on January 11, 2019. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Beclomethasone and Albuterol in Mild Asthma.
- Author
-
Papi, Alberto, Nicolini, Gabriele, and Fabbri, Leonardo M.
- Subjects
- *
LETTERS to the editor , *ASTHMA treatment - Abstract
A reply is presented by Drs. Alberto Papi, Gabriele Nicolini and Leonardo M. Fabbri to letters to the editor about their article "Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma."
- Published
- 2007
- Full Text
- View/download PDF
6. Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial.
- Author
-
Papi, Alberto, Nicolini, Gabriele, Crimi, Nunzio, Fabbri, Leonardo, Olivieri, Dario, Rossi, Andrea, and Paggiaro, Pierluigi
- Abstract
Background: Asthma guidelines suggest that therapy can be reduced once asthma is controlled. Despite these recommendations, asthmatic patients are seldom stepped down in clinical practice, and questions remain about when and how to reduce asthma therapy. The purpose of the present study was to evaluate lung function and asthma control in patients who were stepped down from the highest recommended dose of inhaled corticosteroid/long acting β2 agonist combination therapy.Methods: This was a prospective, randomised, controlled, two-arm parallel group study. Asthmatic patients who were fully controlled with a high daily dose (1000/100 μg) of fluticasone/salmeterol were randomly assigned to 6 months of open-label treatment with either 500/100 μg fluticasone/salmeterol Diskus daily or 400/24 μg extrafine beclomethasone/formoterol pMDI daily. The primary outcome was the change in morning peak expiratory flow (PEF) values between baseline and the end of treatment. The secondary outcomes included asthma control and exacerbation frequency.Results: Four hundred twenty-two patients were included in the analysis. The PEF values remained above 95% of the predicted values throughout the study. The end-study morning PEF rates showed equivalence between the groups (difference between means, 2.49 L/min; 95% CI, -13.43 to 18.42). No changes from baseline were detected in PEF and forced expiratory volume in 1 second measured at the clinics, in the symptom scores or in the use of rescue medication. Asthma control was maintained in 95.2% of the patients at 6 months. No significant differences between the groups were detected in any other parameter, including exacerbation frequency and adverse events.Conclusions: Stepping down patients whose asthma is controlled with the highest recommended dose of fluticasone/salmeterol to either 500/100 μg fluticasone/salmeterol daily or 400/24 μg extra-fine beclomethasone/formoterol daily provides comparable maintenance of lung function and asthma control.Trial Registration: clinicaltrials.gov NCT00497237. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
7. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe.
- Author
-
Budde, Klemens, Rostaing, Lionel, Maggiore, Umberto, Piotti, Giovanni, Surace, Daniela, Geraci, Silvia, Procaccianti, Claudio, Nicolini, Gabriele, Witzke, Oliver, Kamar, Nassim, Albano, Laetitia, Büchler, Matthias, Pascual, Julio, Gutiérrez-Dalmau, Alex, Kuypers, Dirk, Wekerle, Thomas, Głyda, Maciej, Carmellini, Mario, Tisone, Giuseppe, and Midtvedt, Karsten
- Subjects
- *
TACROLIMUS , *KIDNEY transplantation - Published
- 2022
- Full Text
- View/download PDF
8. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe.
- Author
-
Budde, Klemens, Rostaing, Lionel, Maggiore, Umberto, Piotti, Giovanni, Surace, Daniela, Geraci, Silvia, Procaccianti, Claudio, Nicolini, Gabriele, Witzke, Oliver, Kamar, Nassim, Albano, Laetitia, Büchler, Matthias, Pascual, Julio, Gutiérrez-Dalmau, Alex, Kuypers, Dirk, Wekerle, Thomas, Głyda, Maciej, Carmellini, Mario, Tisone, Giuseppe, and Midtvedt, Karsten
- Subjects
- *
KIDNEY transplantation , *TACROLIMUS , *CHRONIC kidney failure - Abstract
Background: Tacrolimus is the calcineurin inhibitor of choice for preventing acute rejection episodes in kidney transplant patients. However, tacrolimus has a narrow therapeutic range that requires regular monitoring of blood concentrations to minimize toxicity. A new once-daily tacrolimus formulation, LCP-tacrolimus (LCPT), has been developed, which uses MeltDose™ drug-delivery technology to control drug release and enhance overall bioavailability. Our study compared dosing of LCPT with current standard-of-care tacrolimus [immediate-release tacrolimus (IR-Tac) or prolonged-release tacrolimus (PR-Tac)] during the 6 months following de novo kidney transplantation. Comparisons of graft function, clinical outcomes, safety, and tolerability for LCPT versus IR-Tac/PR-Tac were also performed. Methods: Standard immunological risk patients with end-stage renal disease who had received a de novo kidney transplant were randomized (1:1) to LCPT (N - 200) or IR-Tac/PR-Tac (N - 201). Results: Least squares (LS) mean tacrolimus total daily dose fromWeek 3 to Month 6 was significantly lower for LCPT than for IR-Tac/PR-Tac. Although LS mean tacrolimus trough levels were significantly higher for LCPT than IR-Tac/PR-Tac, tacrolimus trough levels remained within the standard reference range for most patients. There were no differences between the groups in treatment failure measures or safety profile. Conclusion: LCPT can achieve similar clinical outcomes to other tacrolimus formulations, with a lower daily dose. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study.
- Author
-
Braido, Fulvio, Brusselle, Guy, Guastalla, Daniele, Ingrassia, Eleonora, Nicolini, Gabriele, Price, David, Roche, Nicolas, Soriano, Joan B., Worth, Heinrich, and LIAISON Study Group
- Subjects
- *
ASTHMA prevention , *QUALITY of life , *HUMAN ecology research , *ACTIVE aging , *ASTHMA diagnosis , *DRUG therapy for asthma , *AGE distribution , *ASTHMA , *BRONCHODILATOR agents , *COMPARATIVE studies , *DRUGS , *LONGITUDINAL method , *LUNGS , *RESEARCH methodology , *MEDICAL care costs , *MEDICAL care use , *MEDICAL cooperation , *OBESITY , *PATIENT compliance , *QUESTIONNAIRES , *RESEARCH , *SEASONS , *SEX distribution , *SMOKING , *TIME , *COMORBIDITY , *EVALUATION research , *TREATMENT effectiveness , *CROSS-sectional method , *DISEASE progression , *ECONOMICS , *THERAPEUTICS - Abstract
Background: According to the Global Initiative of Asthma, the aim of asthma treatment is to gain and maintain control. In the INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study, we evaluated the level of asthma control and quality of life (QoL), as well as their determinants and impact in a population consulting specialist settings.Methods: LIAISON is a prospective, multicentre, observational study with a cross-sectional and a 12-month longitudinal phase. Adults with an asthma diagnosis since at least 6 months, receiving the same asthma treatment in the 4 weeks before enrolment were included. Asthma control was assessed with the 6-item Asthma Control Questionnaire (ACQ) and QoL with the MiniAsthma Quality of Life Questionnaire (MiniAQLQ).Results: Overall, 8111 asthmatic patients were enrolled in 12 European countries. Asthma control was suboptimal in 56.5 % of patients and it was associated with poorer asthma-related QoL, higher risk of exacerbations and greater consumption of healthcare resources. Variables associated with suboptimal control were age, gender, obesity, smoking and comorbidities. Major determinants of poor asthma control were seasonal worsening and persisting exposure to allergens/irritants/triggers, followed by treatment-related issues.Conclusions: The cross-sectional phase results confirm that suboptimal control is frequent and has a high individual and economic impact.Trial Registration: The clinicaltrials.gov identifier is NCT01567280 . [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
10. The Heterogeneity Hidden in Allergic Rhinitis and Its Impact on Co-Existing Asthma in Adults: A Population-Based Survey.
- Author
-
antonicelli, Leonardo, Marchetti, Pierpaolo, accordini, Simone, Bono, Roberto, Carosso, aurelia, Casali, Lucio, Cazzoletti, Lucia, Corsico, angelo, Ferrari, Marcello, Fois, alessandro, Nicolini, Gabriele, Olivieri, Mario, Pirina, Pietro, Verlato, Giuseppe, Villani, Simona, and de Marco, Roberto
- Subjects
- *
SINUSITIS , *RHINITIS , *ALLERGIES , *MEDICAL care costs , *EPIDEMIOLOGY - Abstract
Background: It has been suggested that there is some overlap between allergic rhinitis (AR), sinusitis and polyposis, but this has not been fully documented. The present study aimed to evaluate the prevalence of these co-existing diseases and their impact on bronchial asthma in the general population of Italy. Methods: Within the frame of the multicentre Gene Environment Interactions in Respiratory Diseases (GEIRD) study, a postal screening questionnaire including questions about self-reported symptoms of asthma, AR, AR with sinusitis without nasal polyps (AR + SsNP) and AR with sinusitis with nasal polyps (AR + SwNP) was administered. Random samples of subjects aged between 20 and 44 years (n = 5,162) answered the postal questionnaire in 4 Italian centres (Pavia, Sassari, Turin, Verona). In AR subjects, the association among AR only, AR + SsNP, AR + SwNP and bronchial asthma was estimated by the relative risk ratio (RRR) using multinomial regression models. Results: The prevalence of AR in the sample was 25.4% (95% CI 24.2-26.6). A self-reported diagnosis of AR + SsNP and AR + SwNP was reported by 5.7% (95% CI 5.0-6.3) and by 1.2% (95% CI 0.9-1.5) of the subjects, respectively. Current asthma was reported by 17.5% of the AR subjects. In the adjusted multivariate analysis, the risk of having current asthma (RRR = 2.31, 95% CI 1.29-4.15), of having at least 1 asthma attack per year (RRR = 2.30, 95% CI 1.19-4.46) and of having had an emergency department admission for respiratory diseases (RRR = 5.61, 95% CI 1.81-23.92) was higher for subjects with AR + SwNP than subjects with AR only. Conclusions: The diagnosis of AR in the epidemiological setting includes heterogeneous upper airway diseases that affect the clinical features of AR and its interactions with asthma. © 2016 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients.
- Author
-
Alfieri, Veronica, Aiello, Marina, Pisi, Roberta, Tzani, Panagiota, Mariani, Elisa, Marangio, Emilio, Olivieri, Dario, Nicolini, Gabriele, and Chetta, Alfredo
- Subjects
- *
BRONCHOCONSTRICTION , *ASTHMA , *AIRWAY (Anatomy) , *ASTHMATICS , *BRONCHIAL spasm , *METHACHOLINE chloride - Abstract
Background: We investigated whether a relationship between small airways dysfunction and bronchial hyperresponsiveness (BHR), expressed both in terms of ease of airway narrowing and of excessive bronchoconstriction, could be demonstrated in asthma. Methods: 63 (36 F; mean age 42 yr ± 14) stable, mild-to-moderate asthmatic patients (FEV1 92% pred ±14; FEV1/FVC 75% ± 8) underwent the methacholine challenge test (MCT). The degree of BHR was expressed as PD20 (in μg) and as ΔFVC%. Peripheral airway resistance was measured pre- and post-MCT by impulse oscillometry system (IOS) and expressed as R5-R20 (in kPa sL-1). Results: All patients showed BHR to methacholine (PD20 < 1600 μg) with a PD20 geometric (95% CI) mean value of 181(132-249) μg and a ΔFVC% mean value of 13.6% ± 5.1, ranging 2.5 to 29.5%. 30 out of 63 patients had R5-R20 > 0.03 kPa sL-1 (>upper normal limit) and showed ΔFVC%, but not PD20 values significantly different from the 33 patients who had R5-R20 ⩽ 0.03 kPa sL-1 (15.8% ± 4.6 vs 11.5% ± 4.8, p < 0.01 and 156(96-254) μg vs 207 (134-322) μg, p = 0.382). In addition, ΔFVC% values were significantly related to the corresponding pre- (r = 0.451, p < 0.001) and post-MCT (r = 0.376, p < 0.01) R5-R20 values. Conclusions: Our results show that in asthmatic patients, small airway dysfunction, as assessed by IOS, is strictly associated to BHR, expressed as excessive bronchoconstriction, but not as ease of airway narrowing. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Beclomethasone dipropionate and formoterol reduce oxidative/nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial epithelial cells.
- Author
-
Montalbano, Angela Marina, Anzalone, Giulia, Albano, Giusy Daniela, Sano, Caterina Di, Gagliardo, Rosalia, Bonanno, Anna, Riccobono, Loredana, Nicolini, Gabriele, Ingrassia, Eleonora, Gjomarkaj, Mark, and Profita, Mirella
- Subjects
- *
BECLOMETHASONE dipropionate , *FORMOTEROL , *OXIDATIVE stress , *NITROSATION , *PHYSIOLOGICAL effects of tobacco , *INTERLEUKINS , *BRONCHI , *EPITHELIAL cells , *THERAPEUTICS - Abstract
Abstract: Interleukin-17A (IL-17A), cigarette smoke and oxidative/nitrosative stress are involved in inflammatory airway diseases, and the mechanisms behind these processes are still poorly understood. We investigated whether recombinant human IL-17A (rhIL-17A), in combination with cigarette smoke extracts (CSE), increases the levels of inducibile nitric oxide synthase (iNOS), reactive oxygen species, nitrotyrosine (NT) and the activation of signal transducer and activator of transcription 1 (STAT-1) in normal human bronchial epithelial cells (16HBE). The effect of beclomethasone dipropionate (BDP), formoterol and their combination was also evaluated. We demonstrated that rhIL-17A or CSE alone increases iNOS expression, reactive oxygen species and NT production and STAT-1 downstream signalling activation in terms of STAT-1ser727 and STAT-1tyr701 phosphorylation. The combination of both stimuli further increased iNOS, ROS, NT and STAT-1ser727 phosphorylation. The silencing of STAT-1 expression partially reduced the levels of iNOS, reactive oxygen species and NT generated by rhIL-17A and inhibited the effect of CSE alone in 16HBE cells. The treatment of the cells with the MEK1/2 inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis (o-aminophenylmercapto butadiene) abolished the expression of iNOS and STAT-1ser727 phosphorylation generated by rhIL-17A. 16HBE treated with BDP or formoterol alone partially suppressed the effect of IL-17A or CSE on ROS, NT, and STAT-1 activation. Furthermore the use of the drugs in combination showed an additive effect in 16HBE. Our findings demonstrate that IL-17A increases oxidative/nitrosative markers, likely via ERK1/2 downstream signalling and STAT-1 pathway activation in human bronchial epithelial cells. BDP and formoterol treatment reduces this effect showing an additive effect used in combination. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
13. The Coexistence of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Prevalence and Risk Factors in Young, Middle-aged and Elderly People from the General Population
- Author
-
de Marco, Roberto, Pesce, Giancarlo, Marcon, Alessandro, Accordini, Simone, Antonicelli, Leonardo, Bugiani, Massimiliano, Casali, Lucio, Ferrari, Marcello, Nicolini, Gabriele, Panico, Maria Grazia, Pirina, Pietro, Zanolin, Maria Elisabetta, Cerveri, Isa, and Verlato, Giuseppe
- Subjects
- *
ASTHMA , *OBSTRUCTIVE lung diseases , *DISEASES in older people , *STATISTICAL sampling , *RESPIRATORY diseases , *POPULATION biology , *EPIDEMIOLOGY - Abstract
Background: The joint distribution of asthma and chronic obstructive pulmonary disease (COPD) has not been well described. This study aims at determining the prevalence of self-reported physician diagnoses of asthma, COPD and of the asthma-COPD overlap syndrome and to assess whether these conditions share a common set of risk factors. Methods: A screening questionnaire on respiratory symptoms, diagnoses and risk factors was administered by mail or phone to random samples of the general Italian population aged 20–44 (n = 5163) 45–64 (n = 2167) and 65–84 (n = 1030) in the frame of the multicentre Gene Environment Interactions in Respiratory Diseases (GEIRD) study. Results: A physician diagnosis of asthma or COPD (emphysema/chronic bronchitis/COPD) was reported by 13% and 21% of subjects aged <65 and 65–84 years respectively. Aging was associated with a marked decrease in the prevalence of diagnosed asthma (from 8.2% to 1.6%) and with a marked increase in the prevalence of diagnosed COPD (from 3.3% to 13.3%). The prevalence of the overlap of asthma and COPD was 1.6% (1.3%–2.0%), 2.1% (1.5%–2.8%) and 4.5% (3.2%–5.9%) in the 20–44, 45–64 and 65–84 age groups. Subjects with both asthma and COPD diagnoses were more likely to have respiratory symptoms, physical impairment, and to report hospital admissions compared to asthma or COPD alone (p<0.01). Age, sex, education and smoking showed different and sometimes opposite associations with the three conditions. Conclusion: Asthma and COPD are common in the general population, and they coexist in a substantial proportion of subjects. The asthma-COPD overlap syndrome represents an important clinical phenotype that deserves more medical attention and further research. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. 1-year prospective real life monitoring of asthma control and quality of life in Italy.
- Author
-
Terzano, Claudio, Cremonesi, Giovanni, Girbino, Giuseppe, Ingrassia, Eleonora, Marsico, Serafino, Nicolini, Gabriele, and Allegra, Luigi
- Subjects
- *
ASTHMA prevention , *ASTHMATICS , *QUALITY of life , *DISEASE exacerbation - Abstract
Objectives: The study aimed at prospectively evaluating the evolution of asthma control in Italy, to evaluate the reasons for lack of asthma control, perceived quality of life (QoL) and association with level of asthma control, the impact of pharmacological treatment, the number of exacerbations and the healthcare resource consumption. Methods: PRISMA (PRospectIve Study on asthMA control) was an observational study performed in asthmatic patients including a cross-sectional phase and a 12-month prospective phase. Asthma control was assessed with the Asthma Control Test™ (ACT) and QoL was evaluated with EuroQoL-5D questionnaire filled in and collected during 5 clinic visits together with all the other data. Results: The prospective phase included 1017 patients with uncontrolled (55.7%) or partly controlled asthma (44.3%). Out of the 739 patients evaluable after 12 months, 22.2% achieved full asthma control (ACT score = 25) and 58.7% reached a good control (ACT score: 20-24). The improvement in asthma control was associated with improved QoL and reduced hospital visits. The main reasons for lack of asthma control were comorbidities, continued exposure to irritants/triggers and poor adherence to therapy. The frequency of exacerbations was lower in patients with controlled asthma. A fixed combination therapy with an inhaled corticosteroid and a long-acting β2 agonist was reported by 77.0% of patients. A better asthma control and improved QoL were achieved with extrafine beclomethasone/formoterol compared to either budesonide/formoterol or fluticasone/salmeterol. Conclusions: An improvement in asthma control and QoL can be achieved during a 1-year monitoring in a real life setting. Extrafine beclomethasone/formoterol was associated with significant benefit in terms of asthma control and QoL compared to large-particles combinations. ClinicalTrials.gov number NCT01110460. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma.
- Author
-
Papi, Alberto, Canonica, Giorgio W., Maestrelli, Piero, Paggiaro, Pierluigi, Olivieri, Dario, Pozzi, Ernesto, Crimi, Nunzio, Vignola, Antonio M., Morelli, Paolo, Nicolini, Gabriele, and Fabbri, Leonardo M.
- Subjects
- *
ASTHMA treatment , *BECLOMETHASONE dipropionate , *ALBUTEROL , *INHALERS , *ADRENOCORTICAL hormones , *MEDICAL research , *OBSTRUCTIVE lung disease treatment , *PLACEBOS , *ASTHMATICS , *THERAPEUTICS - Abstract
Background: Treatment guidelines recommend the regular use of inhaled corticosteroids for patients with mild persistent asthma. We investigated whether the symptom-driven use of a combination of beclomethasone dipropionate and albuterol (also known as salbutamol) in a single inhaler would be as effective as the regular use of inhaled beclomethasone and superior to the as-needed use of inhaled albuterol. Methods: We conducted a 6-month, double-blind, double-dummy, randomized, parallel-group trial. After a 4-week run-in, patients with mild asthma were randomly assigned to receive one of four inhaled treatments: placebo twice daily plus 250 μg of beclomethasone and 100 μg of albuterol in a single inhaler as needed (as-needed combination therapy); placebo twice daily plus 100 μg of albuterol as needed (as-needed albuterol therapy); 250 μg of beclomethasone twice daily and 100 μg of albuterol as needed (regular beclomethasone therapy); or 250 μg of beclomethasone and 100 μg of albuterol in a single inhaler twice daily plus 100 μg of albuterol as needed (regular combination therapy). The primary outcome was the morning peak expiratory flow rate. Results: In 455 patients with mild asthma who had a forced expiratory volume in 1 second of 2.96 liters (88.36% of the predicted value), the morning peak expiratory flow rate during the last 2 weeks of the 6-month treatment was higher (P=0.04) and the number of exacerbations during the 6-month treatment was lower (P=0.002) in the as-needed combination therapy group than in the as-needed albuterol therapy group, but the values in the as-needed combination therapy group were not significantly different from those in the groups receiving regular beclomethasone therapy or regular combination therapy. The cumulative dose of inhaled beclomethasone was lower in the as-needed combination therapy group than in the groups receiving regular beclomethasone therapy or regular combination therapy (P<0.001 for both comparisons). Conclusions: In patients with mild asthma, the symptom-driven use of inhaled beclomethasone (250 μg) and albuterol (100 μg) in a single inhaler is as effective as regular use of inhaled beclomethasone (250 μg twice daily) and is associated with a lower 6-month cumulative dose of the inhaled corticosteroid. (ClinicalTrials.gov number, NCT00382889.) N Engl J Med 2007;356:2040-52. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
16. Correction to: Socioeconomic inequalities in smoking habits are still increasing in Italy.
- Author
-
Verlato, Giuseppe, Accordini, Simone, Nguyen, Giang, Marchetti, Pierpaolo, Cazzoletti, Lucia, Ferrari, Marcello, Antonicelli, Leonardo, Attena, Francesco, Bellisario, Valeria, Bono, Roberto, Briziarelli, Lamberto, Casali, Lucio, Corsico, Angelo Guido, Fois, Alessandro, Panico, Maria Grazia, Piccioni, Pavilio, Pirina, Pietro, Villani, Simona, Nicolini, Gabriele, and de Marco, Roberto
- Subjects
- *
SOCIOECONOMICS , *RESEARCH funding - Published
- 2017
- Full Text
- View/download PDF
17. Socioeconomic inequalities in smoking habits are still increasing in Italy.
- Author
-
Verlato, Giuseppe, Accordini, Simone, Nguyen, Giang, Marchetti, Pierpaolo, Cazzoletti, Lucia, Ferrari, Marcello, Antonicelli, Leonardo, Attena, Francesco, Bellisario, Valeria, Bono, Roberto, Briziarelli, Lamberto, Casali, Lucio, Corsico, Angelo Guido, Fois, Alessandro, Panico, MariaGrazia, Piccioni, Pavilio, Pirina, Pietro, Villani, Simona, Nicolini, Gabriele, and de Marco, Roberto
- Abstract
Background: Socioeconomic inequalities in smoking habits have stabilized in many Western countries. This study aimed at evaluating whether socioeconomic disparities in smoking habits are still enlarging in Italy and at comparing the impact of education and occupation.Methods: In the frame of the GEIRD study (Gene Environment Interactions in Respiratory Diseases) 10,494 subjects, randomly selected from the general population aged 20-44 years in seven Italian centres, answered a screening questionnaire between 2007 and 2010 (response percentage = 57.2%). In four centres a repeated cross-sectional survey was performed: smoking prevalence recorded in GEIRD was compared with prevalence recorded between 1998 and 2000 in the Italian Study of Asthma in Young Adults (ISAYA).Results: Current smoking was twice as prevalent in people with a primary/secondary school certificate (40-43%) compared with people with an academic degree (20%), and among unemployed and workmen (39%) compared with managers and clerks (20-22%). In multivariable analysis smoking habits were more affected by education level than by occupation. From the first to the second survey the prevalence of ever smokers markedly decreased among housewives, managers, businessmen and free-lancers, while ever smoking became even more common among unemployed (time-occupation interaction: p = 0.047). At variance, the increasing trend in smoking cessation was not modified by occupation.Conclusion: Smoking prevalence has declined in Italy during the last decade among the higher socioeconomic classes, but not among the lower. This enlarging socioeconomic inequality mainly reflects a different trend in smoking initiation. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
18. 1-year prospective real life monitoring of asthma control and quality of life in Italy.
- Author
-
Terzano, Claudio, Cremonesi, Giovanni, Girbino, Giuseppe, Ingrassia, Eleonora, Marsico, Serafino, Nicolini, Gabriele, Allegra, Luigi, and PRISMA (PRospectIve Study on asthMA control) Study Group
- Abstract
Objectives: The study aimed at prospectively evaluating the evolution of asthma control in Italy, to evaluate the reasons for lack of asthma control, perceived quality of life (QoL) and association with level of asthma control, the impact of pharmacological treatment, the number of exacerbations and the healthcare resource consumption.Methods: PRISMA (PRospectIve Study on asthMA control) was an observational study performed in asthmatic patients including a cross-sectional phase and a 12-month prospective phase. Asthma control was assessed with the Asthma Control Test™ (ACT) and QoL was evaluated with EuroQoL-5D questionnaire filled in and collected during 5 clinic visits together with all the other data.Results: The prospective phase included 1017 patients with uncontrolled (55.7%) or partly controlled asthma (44.3%). Out of the 739 patients evaluable after 12 months, 22.2% achieved full asthma control (ACT score = 25) and 58.7% reached a good control (ACT score: 20-24). The improvement in asthma control was associated with improved QoL and reduced hospital visits. The main reasons for lack of asthma control were comorbidities, continued exposure to irritants/triggers and poor adherence to therapy. The frequency of exacerbations was lower in patients with controlled asthma.A fixed combination therapy with an inhaled corticosteroid and a long-acting β2 agonist was reported by 77.0% of patients. A better asthma control and improved QoL were achieved with extrafine beclomethasone/formoterol compared to either budesonide/formoterol or fluticasone/salmeterol.Conclusions: An improvement in asthma control and QoL can be achieved during a 1-year monitoring in a real life setting. Extrafine beclomethasone/formoterol was associated with significant benefit in terms of asthma control and QoL compared to large-particles combinations.ClinicalTrials.gov number NCT01110460. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
19. Inhaled steroid/tobacco smoke particle interactions: a new light on steroid resistance.
- Author
-
Invernizzi G, Ruprecht A, De Marco C, Mazza R, Nicolini G, Boffi R, Invernizzi, Giovanni, Ruprecht, Ario, De Marco, Cinzia, Mazza, Roberto, Nicolini, Gabriele, and Boffi, Roberto
- Abstract
Background: Inhaled steroid resistance is an obstacle to asthma control in asthmatic smokers. The reasons of this phenomenon are not yet entirely understood. Interaction of drug particles with environmental tobacco smoke (ETS) could change the aerodynamic profile of the drug through the particle coagulation phenomenon. Aim of the present study was to examine whether steroid particles interact with smoke when delivered in the presence of ETS.Methods: Beclomethasone-hydrofluoralkane (BDP-HFA) pMDI particle profile was studied after a single actuation delivered in ambient air or in the presence of ETS in an experimental chamber using a light scattering Optical Particle Counter capable of measuring the concentrations of particle sized 0.3-1.0, 1.1-2.0, 2.1-3.0, 3.1-4.0, 4.1-5.0, and > 5.1 microm in diameter with a sampling time of one second. The number of drug particles delivered after a single actuation was measured as the difference between total particle number after drug delivery and background particle number. Two groups of experiments were carried out at different ambient background particle concentrations. Two-tail Student's t-test was used for statistical analysis.Results: When delivered in ambient air, over 90% of BDP-HFA particles were found in the 0.3-1.0 microm size class, while particles sized 1.1-2.0 microm and 2.1-3.0 represented less than 6.6% and 2.8% of total particles, respectively. However, when delivered in the presence of ETS, drug particle profile was modified, with an impressive decrease of 0.3-1.0 microm particles, the most represented particles resulting those sized 1.1-2.0 microm (over 66.6% of total particles), and 2.1-3.0 microm particles accounting up to 31% of total particles.Conclusion: Our data suggest that particle interaction between inhaled BDP-HFA pMDI and ETS takes place in the first few seconds after drug delivery, with a decrease in smaller particles and a concurrent increase of larger particles. The resulting changes in aerosol particle profile might modify regional drug deposition with potential detriment to drug efficacy, and represent a new element of steroid resistance in smokers. Although the present study does not provide any functional or clinical assessment, it might be useful to advise smokers and non smokers with obstructive lung disease such as asthma or COPD, to avoid to act inhaled drugs in the presence of ETS in order to obtain the best therapeutic effect. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.